Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

BACKGROUND: In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for major CV adverse events. However, there was...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Diabetol
Glavni autori: Pollack, Pia S., Chadwick, Kristina D., Smith, David M., Billger, Martin, Hirshberg, Boaz, Iqbal, Nayyar, Boulton, David W.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5598064/
https://ncbi.nlm.nih.gov/pubmed/28903775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0595-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items